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Abstract: Osteoarthritis (OA) is a progressive joint disease that causes significant disability and pain
and for which there are limited treatment options. We posit that delivery of anabolic factors that protect
and maintain cartilage homeostasis will halt or retard OA progression. We employ a peptide-based
nanoplatform to deliver Wingless and the name Int-1 (WNT) 16 messenger RNA (mRNA) to human
cartilage explants. The peptide forms a self-assembled nanocomplex of approximately 65 nm in
size when incubated with WNT16 mRNA. The complex is further stabilized with hyaluronic acid
(HA) for enhanced cellular uptake. Delivery of peptide-WNT16 mRNA nanocomplex to human
cartilage explants antagonizes canonical β-catenin/WNT3a signaling, leading to increased lubricin
production and decreased chondrocyte apoptosis. This is a proof-of-concept study showing that
mRNA can be efficiently delivered to articular cartilage, an avascular tissue that is poorly accessible
even when drugs are intra-articularly (IA) administered. The ability to accommodate a wide range of
oligonucleotides suggests that this platform may find use in a broad range of clinical applications.
Keywords: nanoparticle; mRNA delivery; osteoarthritis

1. Introduction
Osteoarthritis (OA) is a progressive disease that causes significant pain and suffering and for
which there are limited medical treatment options. Although effective disease-modifying OA drugs
(DMOADs) are critically needed, none has successfully emerged in the clinic [1]. The reasons for this
failure are multifold, including the fact that primary OA is a complex, multifactorial disease with
incompletely understood pathogenesis [2].
Much interest has recently focused on the role of inflammation and inflammatory cytokines
in the pathogenesis of OA [3]. It is posited that an imbalance between inflammatory (catabolic)
and anabolic factors leads to cartilage degeneration, a hallmark of OA. Thus, blockade of catabolic
cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) has gained
attention as potential therapy. Indeed, intra-articular (IA) administration of IL-1 receptor antagonist
(IL-1ra) exhibits disease-modifying effects in a rodent model of OA [3]. However, in clinical studies,
the administration of commercially available IL-1ra (Anakinra, Kineret® ) had no therapeutic effect
in established knee OA [4] and so far, only offers short-term improvement in pain and function if
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administered within the first month following knee injury (NCT00332254) [5]. Thus, novel approaches
that promote and/or maintain joint homeostasis to mitigate OA progression are highly desirable.
Wingless and the name Int-1 (WNT) comprises an evolutionarily conserved family of glycoproteins
that signal through different pathways. Beta (β)-catenin-dependent (or canonical) WNT signaling leads
to the nuclear translocation of β-catenin and transcriptional activation of target genes that regulate many
crucial aspects of cell fate and function during embryogenesis [6] Non-canonical, β-catenin-independent
WNT signaling pathways and function on the other hand are less well understood [7]. The WNT
signaling pathway has been implicated in the pathogenesis of OA [8]. WNT3a-dependent activation of
the canonical β-catenin-dependent WNT signaling pathway stimulates catabolic activities, resulting
in an OA-like phenotype [9,10]. In contrast, WNT16-deficiency leads to more severe OA in a rodent
model, with increased chondrocyte apoptosis and decreased expression of lubricin [11], an essential
joint lubricant [12]. In vivo injection of recombinant WNT16 in a Xenopus assay buffers the activation
of canonical WNT3a [11]. Thus, we posit that overexpression of WNT16 antagonizes canonical WNT
signaling to halt cartilage loss and mitigate the progression of OA.
The delivery of ribonucleic acids (RNA), small interfering RNA (siRNA), messenger RNA
(mRNA), and microRNA (miRNA) into cells has been attempted using a variety of platforms, including
lipid-based nanocarriers [13]. However, once taken up inside the cells, these particles are often
trapped inside endosomes, with slow release of the RNA structures. Herein, we employ a cytolytic
peptide, melittin, that has been modified to significantly attenuate its pore-forming capacity while
maintaining its ability to insert into membrane bilayers [14–16], as well as improving its interactions
with oligonucleotides [17,18]. Our previous work has shown that the modified peptide, called p5RHH,
forms a self-assembled nanostructure that facilitates endosomal escape and rapidly delivers siRNA
to the cytoplasm, to down-modulate specific gene expression in vitro and in vivo [17–20]. To our
knowledge, the delivery of mRNA using p5RHH for WNT16 overexpression has not been reported.
Herein, we present a proof-of-concept study showing that WNT16 mRNA can be efficiently delivered
to articular cartilage and that its overexpression modulates cartilage homeostasis ex vivo.
2. Results
2.1. Hyaluronic Acid (HA) Coating Enhances Cellular Uptake of the Nanoparticle (NP)
HA, a naturally occurring and highly biocompatible linear polysaccharide that is a major
component of the extracellular matrix (ECM), is present in high concentration in the synovial fluid and
hyaline cartilage and binds to the surface receptor CD44 expressed on chondrocytes [21]. We posit that
functionalization of the NPs with an HA coating will enhance cellular uptake through the interaction
with CD44. Indeed, HA coating significantly enhanced cellular interaction and uptake of the NPs
(Figure 1). We have previously shown that the self-assembled p5RHH-siRNA NPs deeply penetrate
human cartilage to deliver the RNA load to chondrocytes [20]. In the present study we showed that
the HA coating did not lead to increased NP interaction and accumulation in the superficial layer or
prevent the penetration of the NPs into the deep zones of cartilage (Figure 2).
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Figure 2. Cy3-labeled HA-NPs (~55 nm) were incubated with 5 mm22 cartilage discs from human OA
Figure 2. Cy3-labeled HA-NPs (~55 nm) were incubated with 5 mm cartilage discs from human OA
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p5RHH with 1 µg of WNT16 mRNA (peptide:mRNA ratio 3500:1) yielded a NP of ~65 nm after

Pharmaceutics 2020, 12, 73
Pharmaceutics 2020, 12, x FOR PEER REVIEW

4 of 12
4 of 12

application of the HA coating, as measured by transmission electron microscopy (TEM, Figure 3),
and
potential
of ~30
dynamic
light scattering
(DLS, Table(DLS,
1). Increasing
concentration
and aazeta
zeta
potential
of mV
~30bymV
by dynamic
light scattering
Table 1).theIncreasing
the
of
mRNA resulted
in a significantly
particle
diameter
(>200
nm by(>200
TEMnm
at an
mRNA
concentration
of mRNA
resulted in a increased
significantly
increased
particle
diameter
by TEM
at
concentration
of
4
µg
and
a
peptide:mRNA
ratio
of
875:1,
Figure
1A)
and
marked
heterogeneity
in
an mRNA concentration of 4 µg and a peptide:mRNA ratio of 875:1, Figure 1A) and marked
the
sizes of the in
NPs.
larger
NP NPs.
size measured
byNP
DLSsize
(Table
1) suggests
smaller
heterogeneity
theThe
sizes
of the
The larger
measured
by aggregates
DLS (Tablefrom
1) suggests
particles,
which
supported
by thewhich
TEM images
(Figure
right
panel).
While
DLS is
calculation
aggregates
fromissmaller
particles,
is supported
by3,the
TEM
images
(Figure
3, aright
panel).
that
fits
the
light
scattering
data
to
an
algorithm
based
on
Mies
scattering
theory,
TEM
allows
for
direct
While DLS is a calculation that fits the light scattering data to an algorithm based on Mies scattering
visualization
the transfective
particles andof
exclusion
of the larger
aggregates
from theofcalculation,
theory, TEM of
allows
for direct visualization
the transfective
particles
and exclusion
the larger
which
we know,
transfective
from
work
aggregates
from are
the not
calculation,
which
weprior
know,
are [17,18].
not transfective from prior work [17,18].

Figure
with
1
Figure 3.
3. HA-coated p5RHH-WNT16
p5RHH-WNT16mRNA
mRNANPs
NPswere
weregenerated
generatedby
bymixing
mixing1010µmol
µmolofofp5RHH
p5RHH
with
µg
mRNA
(peptide:mRNA
ratio
3500:1),
2
µg
of
mRNA
(peptide:mRNA
ratio
of
1750:1),
or
4
µg
of
1 µg mRNA (peptide:mRNA ratio 3500:1), 2 µg of mRNA (peptide:mRNA ratio of 1750:1), or 4 µg of
mRNA
mRNA (peptide:mRNA
(peptide:mRNA ratio
ratio 875:1).
875:1). Inset (in the left panel)
panel) shows
shows the
the NP
NP at
at aa higher
higher magnification.
magnification.
Table 1. Characteristics of NPs at various peptide:mRNA ratios.
Table 1. Characteristics of NPs at various peptide:mRNA ratios.
Particle Composition
Particle Composition
Peptide:mRNA
Peptide:mRNA
(mol:mol)

3500:1

3500:1

(mol:mol)

1750:1

1750:1

Average size (nm)
64.78 ± 8.344
105.5 ± 6.959
Average
64.78
± 6.959
TEM size (nm)
(n
= 50)± 8.344 105.5
(n = 150)
Average size
(nm)
TEM
(n = 50)
(n = 150)
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DLS size (nm)
Average
Zeta potential (mV)
−30.06 ±181
0.82
−28.79177
± 1.77

875:1

875:1

205.1 ± 6.109

205.1
6.109
(n =± 500)
(n = 500)
3000

3000
−31.48
± 2.59
DLS
NP size was assessed by DLS and TEM and calculated according to the formula detailed in the materials and
Zeta potential (mV)
–30.06 ± 0.82 –28.79 ± 1.77 –31.48 ± 2.59
methods section. n = number of NPs assessed per condition.

NP size was assessed by DLS and TEM and calculated according to the formula detailed in the
materialsofand
methods
section.
n = number
of NPs
assessed
per condition.
2.3. Delivery
Enhanced
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Protein
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mRNA
in Cartilage Explants

To beginofexploring
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of our
nanoplatform
the delivery
of mRNA to express
2.3. Delivery
Enhancedthe
Green
Fluorescent Protein
(eGFP)
mRNA in in
Cartilage
Explants
anabolic factors, we first used eGFP mRNA (~1000 nt) for ease of detection of the translated product.
To begin exploring the efficacy/efficiency of our nanoplatform in the delivery of mRNA to
HA-coated p5RHH-eGFP mRNA NPs were prepared, as detailed in Materials and Methods and added
express 2anabolic factors, we first used eGFP mRNA (~1000 nt) for ease of detection of the translated
to 5 mm cartilage discs from human OA knee joints. The cartilage explants were harvested after 48 h
product. HA-coated p5RHH-eGFP mRNA NPs were prepared, as detailed in Materials and Methods
in culture and examined
for eGFP expression. We observed efficient cartilage expression of eGFP with
and added to 5 mm2 cartilage discs from human OA knee joints. The cartilage explants were
transfection of the NPs (Figure 4).
harvested after 48 h in culture and examined for eGFP expression. We observed efficient cartilage
expression of eGFP with transfection of the NPs (Figure 4).
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Figure 4. HA-coated p5RHH-eGFP mRNA NPs at 1 µg of mRNA and 10 µmol of p5RHH were
Figure 4. HA-coated2 p5RHH-eGFP mRNA NPs at 1 µg of mRNA and 10 µmol of p5RHH were
incubated with 5 mm cartilage discs derived from human OA knee joints. After 48 h, cartilage explants
incubated with 5 mm2 cartilage discs derived from human OA knee joints. After 48 h, cartilage
were washed, processed, and examined for eGFP expression (green). (A) eGFP expression was detected
explants were washed, processed, and examined for eGFP expression (green). (A) eGFP expression
in all layers of cartilage. (B) Higher magnification revealed eGFP expression in chondrocytes residing
was detected in all layers of cartilage. (B) Higher magnification revealed eGFP expression in
in the deep zone of cartilage. DAPI stains nuclei blue. Scale bar = 25 µm. (C) Mean eGFP fluorescent
chondrocytes residing in the deep zone of cartilage. DAPI stains nuclei blue. Scale bar = 25 µm. (C)
intensity ± SEM per chondrocyte (n = 20 chondrocytes assessed per treatment condition). N = 3
Mean eGFP fluorescent intensity ± SEM per chondrocyte (n = 20 chondrocytes assessed per treatment
cartilage discs per treatment. Scale bar = 25 µm, *** p < 0.001.
condition). N = 3 cartilage discs per treatment. Scale bar = 25 µm, *** p < 0.001.

2.4. Delivery of WNT16 mRNA in Cartilage Explants
2.4. Delivery of WNT16 mRNA in Cartilage Explants
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expression
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with
the delivery
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2 µg, that
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WNT16
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significantly
the delivery ofNPs
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µg and 2 µg,(4
but
not
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(Figure
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becauseenhanced
the size ofwith
the self-assembled
at this
µg)
of at
mRNA
(Figure
likely
because
the size
of the self-assembled
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penetration.
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expression
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big
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was
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decreased β-catenin (Figure 5C,D) and WNT3a (Figure 5E,F).
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Figure 5. HA-coated p5RHH-WNT16 mRNA NPs generated at the indicated concentrations of mRNA
Figure 5. HA-coated p5RHH-WNT16 mRNA
NPs generated at the indicated concentrations of mRNA
and p5RHH were incubated with 5 mm2 cartilage discs derived from human OA knee joints. After
and p5RHH were incubated with 5 mm2 cartilage discs derived from human OA knee joints. After 48
48 h, cartilage explants were washed, processed, and examined for WNT16 (A,B), Beta-catenin (C,D),
h, cartilage explants were washed, processed, and examined for WNT16 (A,B), Beta-catenin (C,D),
and WNT3a (E,F) expression. Immunohistochemistry (IHC) photomicrographs were derived from
and WNT3a (E,F) expression. Immunohistochemistry (IHC) photomicrographs were derived from
cartilage discs transfected with 1 µg of peptide-mRNA NPs. Scale bar = 100 µm. The numbers of
cartilage discs transfected with 1 µg of peptide-mRNA NPs. Scale bar = 100 µm. The numbers of
WNT16+, beta-catenin+, and WNT3a+ cells/cartilage section were enumerated. Values represent
WNT16+, beta-catenin+, and WNT3a+ cells/cartilage section were enumerated. Values represent mean
mean ± SEM. Data were derived from 6 to 8 cartilage sections, from 4–6 independent human cartilage
± SEM. Data were derived from 6 to 8 cartilage sections, from 4–6 independent human cartilage
explants. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant.
explants. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant.

2.5. Effect of WNT16 Overexpression on Cartilage Homeostasis
2.5. Effect of WNT16 Overexpression on Cartilage Homeostasis
We examined the downstream effects following the delivery of the NPs. We chose the NPs
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Figure
6. HA-coated
p5RHH-WNT16 mRNA
mRNA NPs
at at
1 µg
of mRNA
and and
10 µmol
of
Figure
6. HA-coated
p5RHH-WNT16
NPs(generated
(generated
1 µg
of mRNA
10 µmol
of
22cartilage discs derived from human OA knee joints. After 48 h,
p5RHH)
were
incubated
with
5
mm
p5RHH) were incubated with 5 mm cartilage discs derived from human OA knee joints. After
explants
were
washed,
processed,
and examined
for lubricin
expression
and terminal
48 h,cartilage
cartilage
explants
were
washed,
processed,
and examined
for
lubricin (A,B)
expression
(A,B) and
deoxynucleotidyl transferase and nick-end labeling (TUNEL)+ cells (C,D). Scale bar = 100 µm. The
terminal deoxynucleotidyl transferase and nick-end labeling (TUNEL)+ cells (C,D). Scale bar = 100 µm.
numbers of Lubricin+ and TUNEL+ cells/cartilage section were enumerated. Values represent mean
The numbers of Lubricin+ and TUNEL+ cells/cartilage section were enumerated. Values represent
± SEM. Data were derived from 6–8 cartilage sections, from 4–6 independent human cartilage explants.
mean ± SEM. Data were derived from 6–8 cartilage sections, from 4–6 independent human cartilage
*** p < 0.001.
explants. *** p < 0.001.

3. Discussion

3. Discussion

The challenge of delivering nanotherapeutics to cartilage in effective doses in vivo is well known
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induces new cartilage formation [26]. Sprifermin (AS902330), a recombinant form of human FGF-18
cartilage
repair and homeostasis. Fibroblast growth factors (FGFs) are important regulators of cartilage
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Likewise,
excessivein(β-catenin-dependent)
canonical
WNT new
cartilage formation [26]. Sprifermin (AS902330), a recombinant form of human FGF-18 injected IA in
patients with advanced or end-stage OA shows early promise; however, durability of response at two
years was uncertain [27]. Likewise, excessive (β-catenin-dependent) canonical WNT activation leads to
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cartilage breakdown and increases risk of OA [8,28,29]. A small molecule inhibitor of the WNT pathway
(SM04690) shows protective and regenerative effects in an OA animal model [30] and has the potential
to be disease modifying in knee OA; however, long-term effects are still unknown (ongoing trials
NCT03727022). In the present study, we show that overexpression of WNT16 suppresses canonical
β-catenin/WNT3a signaling. We envision that the p5RHH platform, by its ability to accommodate
a wide range of oligonucleotide structures (siRNA, mRNA, and others) without the need for backbone
or end-piece alterations, will enable the delivery of a “cocktail” of factors (anti-inflammatory and
anabolic) that should control cartilage loss and maintain homeostasis, mitigating OA progression.
In conclusion, we have shown that melittin-derived p5RHH peptide self-assembles with mRNA
to form stable nanostructures that deeply penetrate cartilage for efficient expression of WNT16 ex
vivo. These results hold promise that this approach will overcome the shortcoming of slow RNA
release encountered by lipid-based NPs [13]. In future studies, we will test the effectiveness of WNT16
overexpression in maintaining cartilage homeostasis in vivo.
4. Materials and Methods
4.1. Preparation of HA-Coated p5RHH-mRNA NPs
Ten milligrams of sodium hyaluronic acid (part# HA1M-1, Lifecore Biomedical, Chaska, MN,
USA) was dissolved in 1 mL HBSS with Ca++/Mg++ by sonification for 60 min and ultracentrifuged
at 90,000g for 40 m. The supernatant was aliquoted and stored at −80 ◦ C until use. p5RHH peptide
(VLTTGLPALISWIRRRHRRHC, provided by Genscript, Piscataway, NJ, USA) was dissolved at 10 mM
in DNase-, RNase-, and protease-free sterile purified water (Cellgro at Corning, Tewksbury, MA, USA)
and stored in 10 µL aliquots at −80 ◦ C until use.
The p5RHH-Cy3-labeled siRNA NPs were prepared as previously described [20,31].
The p5RHH-mRNA NPs were prepared as follows: 1 µg of Cy5-eGFP mRNA (TriLink Biotechnologies,
San Diego, CA, USA), or 1, 2, or 4 µg of WNT16 mRNA (TriLink Biotechnologies) in HBSS with Ca++/Mg++
were added to 10 µmol of p5RHH peptide (in a total volume of 100 µL), mixed well, and incubated at
37 ◦ C for 40 min. After incubation, 5 µL of HA was added to the self-assembled NPs and placed on
ice for 5 min. This mixture was diluted into a total volume of 500 µL with culture medium for in vitro
transfection. NP size was measured by TEM and zeta potential by DLS. To calculate the actual spherical
volume of the NPs from their “flattened” shape acquired during the TEM drying process, we used the
formula for the volume of a right cylinder V = πr2 h, where V = volume, r = radius, and h (height). Height
was assumed to be 1/5th of their flattened diameter. The radius for a sphere of the same volume as the
right cylinder was calculated from the formula V = 4/3πr3 .
4.2. Human Cartilage Explant Culture
Human cartilage explants were obtained from patients, through a protocol (ID # 201104119
approved 01/10/2019) approved by the Washington University in St. Louis Institutional Review
Board (IRB), at the time of total knee arthroplasty. All study participants provided written informed
consent. The de-identified cartilage tissues were washed several times with HBSS containing antibiotics,
then incubated in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) (1:1) medium
containing 10% fetal bovine serum (FBS), penicillin/streptomycin (100 U/0.1 mg/mL), amphotericin
B (0.25 µg/mL), and ciproflaxin (10 µg/mL) in a 6-well plate at 37 ◦ C and 5% CO2 for 2–3 days.
The explants were then transferred to a 96-well plate and subsequently exposed to the aforementioned
p5RHH-mRNA NPs for 48 h. The excess NPs were washed off after 48 h incubation. The cartilage
explants were harvested and then embedded in Tissue-Tek optimal cutting temperature (O.C.T.)
compound (Sakura Finetek, Torrance, CA, USA) and sectioned for analysis.

Pharmaceutics 2020, 12, 73

9 of 12

4.3. In Vitro NP Uptake by Bone-Marrow-Derived Macrophages (BMMφ)
All animal experiments were performed in compliance with guidelines and protocols approved
by the Division of Comparative Medicine at Washington University in St. Louis. The animal protocol
(Animal Welfare Assurance # A-3381-01, approved 02/28/2019) is subjected to annual review and
approval by The Animal Studies Committee of Washington University. Bone marrow from C57BL/6
WT mice (Cat# 000664, Jackson Laboratory, Bar Harbor, ME, USA) was cultured in complete RPMI-1640
medium with 10% fetal bovine serum containing recombinant murine granulocyte-macrophage
colony stimulating factor (GM-CSF) (10 µg/mL, Cat# PMC2015, Thermo Fisher Scientific, Waltham,
MA, USA) for 7 days at 37 ◦ C. Cultured cells were plated in 12-well plates at 0.5 × 106 cells/well
overnight. The cells were starved for 30 min prior to stimulation with 10 µg/mL lipopolysaccharide
(LPS) (Cat# L2762, Sigma-Aldrich, St. Louis, MO, USA) for 15 min. The cells were subsequently
cultured in Opti-Minimum Essential Medium (MEM) (Thermo Fischer Scientific) containing HA-coated
Cy3-labeled NPs or uncoated Cy3-labeled NPs at 37 ◦ C for the indicated times. The cells were collected
with ethylenediaminetetraacetic acid (EDTA) solution (1:10 dilution with phosphate buffered saline
(PBS), spun down, resuspended in Flow Cytometry Staining (FACS) buffer, and analyzed by flow
cytometry. For confocal analysis, cells were cultured and fixed with 4% paraformaldehyde in PBS,
permeabilized with 0.1% Triton X-100/PBS, and blocked with 8% BSA. F-actin (Cat# T7471, 1:200
dilution, Invitrogen at Thermo Fischer Scientific) was added and the cells mounted with VECTASHIELD
containing 4’, 6-diamidino-2-phenylindole (DAPI) (Cat# D3571 Molecular Probes at Thermo Fischer
Scientific). The images were captured by a ZEISS LSM 880 confocal laser scanning microscope.
4.4. TUNEL Assay
The apoptotic assay was performed to identify DNA fragmentation associated with terminal
deoxynucleotidyl transferase-mediated (dUTP) nick end labeling (TUNEL). Detection of apoptotic
cells was performed on non-fixed frozen cartilage sections using an in situ cell death detection kit
(Cat#: 11–684-795–910, Roche at Millipore Sigma, St. Louis, MO, USA). In brief, the cartilage sections
were rinsed with PBS, then permeabilized with 0.5% TWEEN-20/PBS for 15 min, and blocked with 8%
BSA solution. Freshly prepared TUNEL reaction mixture, according to the manufacturer’s protocol,
was applied to the sections for 1 h at 37 ◦ C, rinsed 3 to 5 times with PBS, and probed with COL2
antibody (1:200 dilution, generously provided by L. J. Sandell and M. F. Rai, Washington University,
St. Louis), followed by tetramethylrhodamine (TRITC)-conjugated anti-rat secondary antibody (1:100
dilution, Cat# 712-295-153, Jackson Immuno Research, West Grove, PA, USA), and counterstained
with DAPI (1:1000 dilution, Vector Laboratories, Burlingame, CA, USA). The sections were mounted
with VECTASHIELD mounting medium with DAPI (Cat#: H-1200, Vector Laboratories). The TUNEL+
cells were enumerated across non-overlapped fields. Data represent 6–8 sections per cartilage and
4–6 patients per treatment.
4.5. Confocal Microscopy
After incubation with eGFP mRNA NPs for 48 h, the cartilage explants were harvested and
sectioned. Frozen sections (9 µm) were rinsed, fixed, and covered with VECTASHIELD mounting
medium with DAPI (1:1000, Vector Laboratories) at room temperature. The images were acquired with
a ZEISS LSM 880 confocal laser scanning microscope—15 to 20 cells per section and 3–4 sections were
analyzed with the software ZEN. The data was presented as the mean fluorescent intensity per cell.
4.6. Immunohistochemistry
Formalin-fixed, O.C.T-embedded 9 µm sections of human cartilage explants were probed with
WNT16 (1:100 dilution, Cat# LS-A9629, LifeSpan Biosciences, Seattle, WA, USA), WNT3A (1:100 dilution,
Cat# OABF00803, Aviva Systems Biology, San Diego, CA, USA), Lubricin (1:200 dilution, Cat# 55463,
MP Biomedicals, Irvine, CA, USA), or β-catenin (1:100, Cat# ab16051, Abcam, Cambridge, MA, USA)
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at room temperature for 1 h. After washing, the sections were incubated with the corresponding horse
radish peroxidase (HRP)-conjugated secondary antibodies for 1 h. Data presented were derived from
6–8 cartilage sections. The pattern was confirmed on 4–6 independent human cartilage explants.
4.7. Statistics
Comparisons between two groups were performed by Student’s t-test, and between multiple
groups (≥3) by one-way ANOVA followed by Bonferroni’s correction for multiple comparisons.
Differences between experimental groups at a p value of <0.05 were considered significant.
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